Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults
Clinical Pharmacology in Drug Development · 2024-05 · 13 (5) · 534-548
DOI: 10.1002/cpdd.1379 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 12.02.2024. Verfasst von Caroline A Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA. Hauptthemen laut MEDLINE: Healthy Volunteers, Dose-Response Relationship, Drug. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Arena Pharmaceuticals, San Diego, CA.
Abstract (Originalsprache)
Etrasimod is an investigational, once‐daily, oral, selective sphingosine 1‐phosphate receptor 1,4,5 modulator in development for immune‐mediated inflammatory diseases (IMIDs). Here, we report the human safety, pharmacokinetics, and pharmacodynamics of etrasimod obtained from both a single ascending dose (SAD; 0.1‐5 mg) study and a multiple ascending dose (MAD; 0.35‐3 mg once daily) study. Overall, 99 healthy volunteers (SAD n = 40, MAD n = 59) completed the 2 studies. Evaluated single and multiple doses were well tolerated up to 3 mg without severe adverse events (AEs). Gastrointestinal disorders were the most common etrasimod‐related AEs. Over the evaluated single‐ and multiple‐dose ranges, dose‐proportional and marginally greater‐than‐dose‐proportional etrasimod plasma exposure were observed, respectively. At steady state, etrasimod oral clearance and half‐life mean values ranged from 1.0 to 1.2 L/h and 29.7 to 36.4 hours, respectively. Dose‐dependent total peripheral lymphocyte reductions occurred following etrasimod single and multiple dosing. Etrasimod multiple dosing resulted in reductions from baseline in total lymphocyte counts ranging from 41.1% to 68.8% after 21 days. Lymphocyte counts returned to normal range within 7 days following treatment discontinuation. Heart rate lowering from pretreatment baseline on etrasimod dosing was typically mild, with mean reductions seen after the first dose of up to 19.5 bpm (5 mg dose). The favorable safety, pharmacokinetic, and pharmacodynamic properties of etrasimod in humans supported its further development and warranted its investigation for treatment of IMIDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Arena Pharmaceuticals, A Wholly Owned Subsidiary of Pfizer Inc, San Diego, CA, USA.
- Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
- Excellence Cluster Precision Medicine in Inflammation, Christian-Albrecht University of Kiel, Kiel, Germany.
- Department of Medicine, Division of Gastroenterology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Förderung
- Arena Pharmaceuticals, San Diego, CA
Zitieren
APA
Lee, C. A., Schreiber, S., Bressler, B., Adams, J. W., Oh, D. A., Tang, Y. Q., Zhang, J., Komori, H. K., & Grundy, J. S. (2024). Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults. Clinical Pharmacology in Drug Development, 13(5), 534-548. https://doi.org/10.1002/cpdd.1379
Vancouver
Lee CA, Schreiber S, Bressler B, Adams JW, Oh DA, Tang YQ, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults. Clinical Pharmacology in Drug Development. 2024;13(5):534-548. doi:10.1002/cpdd.1379
BibTeX
@article{Lee2024,
author = {Lee, Caroline A and Schreiber, Stefan and Bressler, Brian and Adams, John W and Oh, Dooman Alexander and Tang, Yong Q and Zhang, Jinkun and Komori, Heather Kiyomi and Grundy, John S},
title = {Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
volume = {13},
number = {5},
pages = {534--548},
doi = {10.1002/cpdd.1379}
}
EUVIMED